Patents by Inventor Chiara Ghiron
Chiara Ghiron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8349831Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.Type: GrantFiled: October 25, 2007Date of Patent: January 8, 2013Assignee: Amgen Inc.Inventors: Thomas S. Coulter, Adam James Davenport, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael Gerard Kelly, Steve Fong Poon, Andrew Tasker, Ning Xi, Qing Ping Zeng
-
Patent number: 8334317Abstract: The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.Type: GrantFiled: October 15, 2008Date of Patent: December 18, 2012Assignee: Amgen Inc.Inventors: Thomas S. Coulter, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael G. Kelly, Philip Miller, Gilbert M. Rishton, David J. St. Jean, Jr., David J. Semin
-
Patent number: 8163729Abstract: The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.Type: GrantFiled: January 16, 2008Date of Patent: April 24, 2012Assignees: Wyeth, Siena Biotech S.p.A.Inventors: Chiara Ghiron, Arianna Nencini, Iolanda Micco, Riccardo Zanaletti, Laura Maccari, Hendrick Bothmann, Simon N. Haydar, Maurizio Varrone, Carmela Pratelli, Boyd L. Harrison
-
Publication number: 20110178133Abstract: The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.Type: ApplicationFiled: October 15, 2008Publication date: July 21, 2011Inventors: Thomas S. Coulter, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael G. Kelly, Philip Miller, Gilbert M. Rishton, David J. St.Jean, JR., David J. Semin
-
Publication number: 20100130474Abstract: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate ?7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.Type: ApplicationFiled: July 16, 2009Publication date: May 27, 2010Applicants: WYETH, SIENA BIOTECH S.P.A.Inventors: Hendrick Bothmann, Chiara Ghiron, Laura Maccari, Iolanda Micco, Arianna Nencini, Riccardo Zanaletti, Simon N. Haydar
-
Publication number: 20100029606Abstract: The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.Type: ApplicationFiled: January 16, 2008Publication date: February 4, 2010Applicants: WYETH, SIENA BIOTECH S.P.A.Inventors: Chiara Ghiron, Arianna Nencini, Iolanda Micco, Riccardo Zanaletti, Laura Maccari, Hendrick Bothmann, Simon N. Haydar, Maurizio Varrone, Carmela Pratelli, Boyd L. Harrison
-
Publication number: 20100016343Abstract: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate ?7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Applicants: WYETH, SIENA BIOTECH S.P.A.Inventors: Chiara Ghiron, Michela Valacchi, Ugo Zanelli, Simon N. Haydar
-
Publication number: 20100016288Abstract: Compounds with ?7 nicotinic acetylcholine receptor (?7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.Type: ApplicationFiled: July 15, 2008Publication date: January 21, 2010Inventors: Hendrick BOTHMANN, Renza Roncarati, Jolanda Micco, Arianna Nencini, Chiara Ghiron
-
Publication number: 20100016360Abstract: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate ?7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Applicants: WYETH, SIENA BIOTECH S.P.A.Inventors: Simon N. Haydar, Chiara Ghiron, Michela Valacchi, Ugo Zanelli
-
Patent number: 7524873Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: January 30, 2007Date of Patent: April 28, 2009Assignee: Amgen Inc.Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Philip Miller, John F. Kincaid, Chiara Ghiron, Thomas S. Coulter
-
Patent number: 7504396Abstract: The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof.Type: GrantFiled: June 23, 2004Date of Patent: March 17, 2009Assignee: Amgen Inc.Inventors: Joseph J. Nunes, Xiaotian Zhu, Patricia Amouzegh, Chiara Ghiron, David N. Johnson, Eoin Christopher Power
-
Publication number: 20080275028Abstract: The present invention relates to compounds with ?7 nAChR agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological, psychiatric, cognitive, immunological and inflammatory disorders.Type: ApplicationFiled: July 19, 2005Publication date: November 6, 2008Inventors: Giovanni Gaviraghi, Chiara Ghiron, Hendrik Bothmann, Renza Roncarati, Georg Christian Terstappenn
-
Publication number: 20080221101Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.Type: ApplicationFiled: October 25, 2007Publication date: September 11, 2008Applicant: Amgen Inc.Inventors: Thomas S. Coulter, Adam James Davenport, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael Gerard Kelly, Steve Fong Poon, Andrew Tasker, Ning Xi, Qing Ping Zeng
-
Patent number: 7291612Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: GrantFiled: May 30, 2006Date of Patent: November 6, 2007Assignee: Active Biotech A.B.Inventors: Ian Richard Matthews, Thomas Stephen Coutler, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Goran Pettersson, Dorthe da Graca Thrige, Philip Huxley
-
Publication number: 20070142381Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: January 30, 2007Publication date: June 21, 2007Inventors: Michael Kelly, Shimin Xu, Ning Xi, Philip Miller, John Kincaid, Chiara Ghiron, Thomas Coulter
-
Patent number: 7196102Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: February 18, 2005Date of Patent: March 27, 2007Assignee: Amgen Inc.Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Philip Miller, John F. Kincaid, Chiara Ghiron, Thomas Coulter
-
Patent number: 7176322Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: May 22, 2003Date of Patent: February 13, 2007Assignee: Amgen Inc.Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Robert Townsend, David Semin, Chiara Ghiron, Thomas Coulter
-
Publication number: 20060217411Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: May 30, 2006Publication date: September 28, 2006Inventors: Ian Matthews, Thomas Coulter, Chiara Ghiron, Chris Brennan, Muhammed Uddin, Lars Pettersson, Dorthe Thrige, Philip Huxley
-
Patent number: 7081456Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: GrantFiled: November 21, 2003Date of Patent: July 25, 2006Assignee: Active Biotech ABInventors: Ian Richard Matthews, Thomas Stephen Coulter, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Göran Pettersson, Dorthe da Graca Thrige, Philip Huxley
-
Publication number: 20050209221Abstract: The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof.Type: ApplicationFiled: June 23, 2004Publication date: September 22, 2005Inventors: Joseph Nunes, Xiaotian Zhu, Patricia Amouzegh, Chiara Ghiron, David Johnston, Eoin Power